4D Molecular Therapeutics, Inc. FDMT R2KR3KPHARMA
Company Overview
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Why Investors Should Care
Revenue has grown at a 51.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $85.21M (+230194.6% YoY); net profit $-140.11M.
- 5-Year Trend Long-term compounding — revenue CAGR 51.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 51.81% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +61.92% |
| 6 Months: | +14.89% |
| 3 Months: | +4.05% |
| 1 Month: | -26.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)33.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 51.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 35.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FDMT 4D Molecular Therapeutics, Inc. R2KR3KPHARMA | 10.80 | -4.11 | $596.64M | 0.00% | -30.52% | -43.25% | 51.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.41M | 3.51M | 7.42M | 2.00M | 14.58M | 1.37M | 1.22M | 162.00K | 500.00K | 298.00K | 239.00K | 20.20M | 28.00K | 5.00K | 3.00K | 14.00K | 15.00K | 90.00K | 3.05M |
| Operating Income | -13.28M | -15.15M | -7.82M | -16.31M | -7.60M | -22.66M | -26.39M | -28.43M | -26.50M | -30.11M | -32.14M | -13.97M | -38.14M | -42.46M | -51.13M | -53.62M | -59.46M | -61.19M | -73.62M |
| Net Income | -13.16M | -15.15M | -7.83M | -16.41M | -7.59M | -22.24M | -26.34M | -28.09M | -25.69M | -28.68M | -29.62M | -10.26M | -32.40M | -34.95M | -43.84M | -47.97M | -54.66M | -56.88M | -68.76M |
| Diluted EPS | - | - | - | - | -0.28 | -0.82 | -0.82 | -0.87 | -0.79 | -0.88 | -0.77 | -0.24 | -0.66 | -0.63 | -0.79 | -0.86 | -0.98 | -1.01 | -1.01 |
| R&D Expense | 13.16M | 15.72M | 11.55M | 12.77M | 15.22M | 15.84M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.96M | 13.36M | 18.04M | 3.13M | 20.72M | 37.00K | 85.21M |
| Operating Income | -50.76M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M | -159.55M |
| Net Income | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M | -140.11M |
| Diluted EPS | - | - | -2.57 | -3.32 | -2.58 | -2.98 | -2.42 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 58.23M | 288.33M | 353.49M | 261.85M | 339.89M | 560.38M | 566.71M |
| Total Equity | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M | 505.66M |
| Cash & Equivalents | - | 49.65M | 276.73M | 153.00M | 52.35M | 249.11M | 149.34M | 60.24M |
| Total Liabilities | - | 28.22M | 31.94M | 34.38M | 30.51M | 32.06M | 49.78M | 61.05M |
| Current Liabilities | - | 12.96M | 16.74M | 16.34M | 15.73M | 18.95M | 29.15M | 43.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M | -134.59M | -109.08M |
| Investing Cash Flow | -3.20M | -1.00M | -172.68M | -17.05M | 115.72M | -302.44M | -92.97M |
| Financing Cash Flow | -2.19M | 278.98M | 118.09M | 3.08M | 156.83M | 337.25M | 112.96M |
| Capital Expenditure | -3.20M | -1.00M | -9.11M | -11.54M | -2.77M | -3.79M | -536.00K |
| Free Cash Flow | -39.91M | -51.91M | -78.24M | -98.22M | -78.56M | -138.37M | -109.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -729.4% | -424.0% | -395.5% | -3,516.5% | -544.6% | -507,678.4% | -187.2% |
| Net Margin % | -708.4% | -424.3% | -395.4% | -3,435.4% | -486.6% | -434,778.4% | -164.4% |
| ROE % | 67.6% | -22.1% | -22.3% | -46.5% | -32.8% | -31.5% | -27.7% |
| ROCE % | -112.1% | -20.9% | -21.2% | -44.7% | -35.2% | -35.4% | -30.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.40% | 5.75M | $76.60M |
| 2 | RA Capital Management, L.P. | 9.14% | 5.05M | $67.31M |
| 3 | Blackrock Inc. | 8.23% | 4.55M | $60.60M |
| 4 | Goldman Sachs Group Inc | 7.71% | 4.26M | $56.77M |
| 5 | Novo Holdings A/S | 5.88% | 3.25M | $43.31M |
| 6 | State Street Corporation | 5.27% | 2.91M | $38.81M |
| 7 | BVF Inc. | 5.21% | 2.88M | $38.38M |
| 8 | T. Rowe Price Investment Management, Inc. | 4.55% | 2.51M | $33.48M |
| 9 | Adage Capital Partners GP L.L.C. | 4.07% | 2.25M | $29.98M |
| 10 | Trails Edge Capital Partners, LP | 4.03% | 2.23M | $29.70M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FDMT
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9oZ3JscmNCNmRMQkpJcWFWa3U4SHB0VkJ2VFpQLVgzZHVMUHJ6Yk44SXEyN3FWZG5hMVNZTnV5X2FCOFZsam9ab2xkS2loNkJF?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
FDMT Jan 2027 6.000 call (FDMT270115C00006000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5fVDZzLVZya0EtdFh3UHo3U2xlR2RFdWlBamFpUTlSQVdVMUVYWVk5emN2ZHhZM2NIRnF5UGtKeHlkYzByTGxYdG8yNDBuR3pKZTQzWE5IWlBlWDFYN3RJaXR5cThDQQ?oc=5" target="_blank">FDMT Jan 2027 6.000 call (FDM…
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow (NASDAQ:FDMT) 2026-10-21 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPU3diOEpGQXVFSEE4cTNEblJ0a29xc19WeVhuQmRMSHlfYmJXR1BILXZtZzlYVkRUSUEtLTlkeFA3VmhkcGhFeHgyaUxyRkpUX2dSemFBWnVRa0tQbnRXejZNV01STFlzSVpaNEU4b3hiNkJ4U0pKMnFVUXNWOVR0Qk04NUtHR0FVR3h3bm…
FDMT Reiterates by HC Wainwright & Co. -- Price Target Maintained at $36 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQbWFycTA3WkIzMVZpS19ENXowa05YdXFhXzF1Y3NDUXlQX3RXX2NMR0hBX1B1cEptNDU0UmtOMkk1OElxVXlrMmMzMjVHcG1FVUVKNkxmZG5LRE9WYzJoX0wtWWlaMDl0WUJWbXpGa05GeEhhWGJqYmVvamtHWjB2ZlMwMk9icFJJUXYzSz…
BofA raises 4D Molecular Therapeutics stock price target on trial data - Investing.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPTnpMMjRqRFQySXhHSzNnM3lWcTI5a05zSDVRaEFoNHM1MjhpU3llQndrX24yZ0xybVFwTVJXUjk1bEtpNkJ5RXBydi1PaVVXMmNaOUpIYUdUeW1obmRMSmx5V3VEZVRIMFFCVkpmS3lrUzdxbTd4SjNHRUhPREF5ZTd3SS1wNzNGSTVtaD…
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - TradingView
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNOExqcEc0VGpoYXNnU3dqeV9SWEJJTHdqMTI0bkJaamhuZUhzVnZ6eEt5anZCZ1JNa1NOZzNjZFVMSG1ndGdYaGprU3o1Y2h3Z1NFZEFOZ003RjNaYmd2bkhwMFZUQzk5WDY5OUlVVFFjcGVpNU9EangzY2dzN2pwS05NQmNiamw4M2pEa0…
FDMT — Frequently Asked Questions
What is the current share price of 4D Molecular Therapeutics, Inc. (FDMT)?
As of 2026-10-23 16:27 PDT, 4D Molecular Therapeutics, Inc. (FDMT) trades at $10.80 on NasdaqGS. Its 52-week range is $6.14 to $16.76.
What is the market capitalisation of FDMT?
4D Molecular Therapeutics, Inc. (FDMT) has a market capitalisation of $596.64M on NasdaqGS.
What is the P/E ratio of FDMT?
FDMT trades at a trailing price-to-earnings (P/E) ratio of -4.11. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.81.
What is the return on equity (ROE) of FDMT?
FDMT has a return on equity (ROE) of -43.25%. Its return on capital employed (ROCE) is -30.52%.
Is FDMT a good stock to buy?
This page provides a data-driven analysis of 4D Molecular Therapeutics, Inc. (FDMT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.